Ashvattha Therapeutics, Inc.
Pharmaceutical ManufacturingView the employees at
Ashvattha Therapeutics, Inc.-
Jyoti Wadhwa Senior Scientist - II, Pharmaceutical Development at Ashvattha Therapeutics
-
San Francisco Bay Area
-
Top 5%
Naze Gul Avci, Ph.D. Senior Scientist - Translational Sciences-
Top 5%
Laurie Liu Finance FP&A-
Saratoga, California, United States
-
Rising Star
Steve Maricich Chief Medical Officer at Ashvattha Therapeutics-
San Francisco Bay Area
-
Top 5%
Overview
Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.
-